Combination chemotherapy in advanced small bowel adenocarcinoma

Christophe Locher, David Malka, Valérie Boige, Pascal Lebray, Dominique Elias, Philippe Lasser, Michel Ducreux

Research output: Contribution to journalReview articlepeer-review

87 Scopus citations

Abstract

Objective: To assess the efficacy of 5-fluorouracil (5-FU) and either platinum compounds or irinotecan in patients with advanced small bowel adenocarcinoma (SBA), for whom data on the efficacy of chemotherapy are scarce. Methods: We reviewed data on all patients with advanced SBA who received chemotherapy over a 9-year period at our institution. Results: Twenty patients with advanced SBA received a median of 6 cycles (range 2-15) of chemotherapy with 5-FU and either cisplatin (n = 15), carboplatin (n = 2), or oxaliplatin (n = 3). The overall response rate was 21%, and median progression-free and overall survival 8 and 14 months, respectively. Toxicity was moderate. Second-line chemotherapy with 5-FU and irinotecan resulted in disease stabilization in 4 (50%) of 8 patients (median progression-free survival: 5 months), and in a biological complete response in another patient with nonmeasurable peritoneal carcinomatosis, allowing surgical cytoreduction surgery and hyperthermic intraperitoneal chemotherapy. No tumor response or disease stabilization was seen among the patients who received protracted venous infusion of 5-FU (n = 4) or infusional 5-FU and cisplatin (n = 1) as second-line chemotherapy. Conclusion: Chemotherapy with 5-FU and platinum compounds seems effective and well-tolerated in patients with advanced SBA. 5-FU-irinotecan combination chemotherapy deserves further investigation in the first-line setting.

Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalOncology
Volume69
Issue number4
DOIs
StatePublished - Nov 2005
Externally publishedYes

Keywords

  • 5-Fluorouracil
  • Chemotherapy
  • Irinotecan
  • Platinum compounds
  • Small bowel adenocarcinoma

Fingerprint

Dive into the research topics of 'Combination chemotherapy in advanced small bowel adenocarcinoma'. Together they form a unique fingerprint.

Cite this